Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,003 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platelets Clear all
Completed No phase listed Observational

Association of Platelet Parameters With Bleeding Severity in Children With ITP

NCT03810352
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 20 Years
Enrollment
95 participants
Timeline
2019 – 2023
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 28, 2026, 8:07 PM EDT
Not yet recruiting Phase 4 Interventional

Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia

NCT06998433
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Platelet-Rich Plasma (PRP) Injections, Saline
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 28, 2026, 8:07 PM EDT
Terminated No phase listed Observational

Bioenergetic Profiling and Cognition in GBM Patients

NCT03939858
View directory record Official record
Conditions
Glioblastoma
Interventions
Cognitive Assessment, Blood Collection, Bioenergetic Profiling
Procedure · Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 28, 2026, 8:07 PM EDT
Completed No phase listed Observational

Platelets as Regulators of Inflammation in Cardiac Surgery

NCT02568410
View directory record Official record
Conditions
Systemic Inflammatory Response Syndrome, Acute Kidney Injury
Interventions
coronary artery bypass grafting using cardiopulmonary bypass
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 28, 2026, 8:07 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Scaling and Root Planning With Localized Delivery of Autogenous Growth Factors- Platelet Rich Fibrin (PRF)

NCT04978324
View directory record Official record
Conditions
Periodontitis Chronic Generalized Severe, Periodontitis Chronic Generalized Moderate
Interventions
leukocyte platelet rich fibrin (L-PRF), Scaling and Root Planing
Biological · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 28, 2026, 8:07 PM EDT
Completed Phase 3 Interventional Results available

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

NCT02907359
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
Guadecitabine, Treatment Choice
Drug · Other
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 28, 2026, 8:07 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Studies of Patient With FPDMM

NCT03854318
View directory record Official record
Conditions
Inherited Hematological Diseases, Rare Diseases, FPDMM
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Day to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 8:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease

NCT00229528
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Paxil-CR
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Oct 28, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee

NCT02844751
View directory record Official record
Conditions
Osteoarthritis
Interventions
[StroMed + platelet rich plasma (PRP)], [PRP] platelet rich plasma
Biological
Lead sponsor
VivaTech International, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Grove City, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 28, 2026, 8:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optimizing Platelet Isolation (The Cell Study)

NCT04470505
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
25 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 28, 2026, 8:07 PM EDT
Not listed Not applicable Interventional

Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer

NCT02402374
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Autologous platelet rich plasma gel, Placebo
Device
Lead sponsor
Regen Lab SA
Industry
Eligibility
18 Years to 95 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 28, 2026, 8:07 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

NCT01268059
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Paclitaxel, MEDI-575
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fountain Valley, California • Oxnard, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 28, 2026, 8:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess Platelet Dysfunction With Verify Now Assay

NCT01167218
View directory record Official record
Conditions
Platelet Aggregation Defects
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 28, 2026, 8:07 PM EDT
Completed Early Phase 1 Interventional

Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine

NCT04522674
View directory record Official record
Conditions
Platelet-Rich Plasma
Interventions
Autologous platelet rich plasma
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 95 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 28, 2026, 8:07 PM EDT
Recruiting Phase 3 Interventional

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 28, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

NCT00047320
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor
Interventions
carboplatin, etoposide, ifosfamide, thiotepa, adjuvant therapy, conventional surgery, neoadjuvant therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 24 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 28, 2026, 8:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thrombin Regulated Platelet Activation

NCT00855296
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 28, 2026, 8:07 PM EDT
Not listed No phase listed Observational

Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

NCT01148407
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 28, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
eltrombopag
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Nyack, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 28, 2026, 8:07 PM EDT
Completed No phase listed Observational

Platelet Function in Patients With Hemophilia A

NCT02093065
View directory record Official record
Conditions
Hemophilia A
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 28, 2026, 8:07 PM EDT
Completed Phase 2 Interventional

Daclizumab to Treat Chronic Immune Thrombocytopenia

NCT00049725
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Daclizumab
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 8:07 PM EDT
Terminated No phase listed Observational Results available

Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)

NCT00594685
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
6 Months and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
21
States / cities
Atlanta, Georgia • Iowa City, Iowa • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 28, 2026, 8:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

NCT00569868
View directory record Official record
Conditions
MULTIPLE MYELOMA
Interventions
Velcade
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 28, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

NCT00367991
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Recombinant human erythropoietin alfa (drug), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 28, 2026, 8:07 PM EDT